For patients and their families during cancer treatment, various resources and temporary housing options aim to ease the ...

A longitudinal assessment of patient-reported outcomes demonstrated that pexidartinib (Turalio) continues to offer clinically meaningful symptom relief with extended use in patients with tenosynovial ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Researchers sought to determine whether MSD HSCT or auto-HSCT would have advantages over chemotherapy in post-remission treatment for patients with AML.

“AI can enhance clinical decision-making for common acute symptoms in a virtual urgent care setting,” the authors write. “Thoughtful integration of AI into clinical practice, combining its strengths ...

Incorporating the 40-GEP test with BWH staging and NCCN risk group significantly improved risk stratification.

Investigators compared oncologic outcomes among patients with tumors in the bladder only vs in the bladder neck/urethra.

Cadonilimab plus lenvatinib showed promising antitumor activity in patients with advanced endometrial cancer who have experienced disease progression after prior platinum-based chemotherapy,” said ...

Physicians should counsel patients considering whether to start treatment for chronic noncancer pain about benefits and harms of cannabis or cannabinoids.

Among 11 evaluable patients, the ORR was 91%, with a composite complete remission rate of 73%. In patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL ...